{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:16:22Z","timestamp":1783336582170,"version":"3.54.6"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK128660"],"award-info":[{"award-number":["R01DK128660"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007451","name":"Cell Science Research Foundation","doi-asserted-by":"publisher","award":["B12021-001"],"award-info":[{"award-number":["B12021-001"]}],"id":[{"id":"10.13039\/100007451","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JST ACT-X","award":["JPMJAX2323"],"award-info":[{"award-number":["JPMJAX2323"]}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics","doi-asserted-by":"publisher","award":["PORTER20F0"],"award-info":[{"award-number":["PORTER20F0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics","doi-asserted-by":"publisher","award":["000541256-SC001-Lue"],"award-info":[{"award-number":["000541256-SC001-Lue"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL153988"],"award-info":[{"award-number":["R01HL153988"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["RM1GM144227"],"award-info":[{"award-number":["RM1GM144227"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Alport syndrome is caused by variants in\n                    <jats:italic>COL4A3<\/jats:italic>\n                    ,\n                    <jats:italic>COL4A4<\/jats:italic>\n                    , or\n                    <jats:italic>COL4A5<\/jats:italic>\n                    , which encode the \u03b13\u03b14\u03b15 chains of type IV collagen. These variants result in defects in the glomerular basement membrane (GBM) and impaired kidney function. Nonsense variants result in truncated proteins lacking the NC1 domain, thereby preventing proper GBM assembly and function and causing the most severe forms of the disease. Restoring full-length protein expression represents a potential therapeutic strategy for Alport syndrome and related disorders. Anticodon-edited transfer RNAs (ACE-tRNAs), which promote premature termination codon (PTC) readthrough, have shown promise in diseases such as cystic fibrosis, but their application in Alport syndrome remains unexplored. To assess the potential of ACE-tRNAs for PTC readthrough of\n                    <jats:italic>COL4A5<\/jats:italic>\n                    nonsense variants, we employed a C-terminal NanoLuc-fused COL4A5 reporter system in which luminescence is produced only upon full-length protein translation. We introduced ACE-tRNAs into HeLa and 293T cells expressing one of four\n                    <jats:italic>COL4A5<\/jats:italic>\n                    nonsense variants (\n                    <jats:italic>S36X, R1563X, S1632X, and R1683X<\/jats:italic>\n                    ) identified in patients with X-linked Alport syndrome. Readthrough efficiency was evaluated via NanoLuc luminescence and western blotting. Furthermore, we assessed the efficiency of ACE-tRNA-restored \u03b13\u03b14\u03b15 heterotrimer formation using a split NanoLuc-based assay. Our results show that application of ACE-tRNAs led to restored C-terminal luminescence across all four COL4A5 nonsense variants, indicating successful readthrough and full-length translation. Moreover, the restored COL4A5 proteins formed \u03b13\u03b14\u03b15 heterotrimers. These findings support ACE-tRNA-mediated nonsense suppression as a promising therapeutic strategy for Alport syndrome, with the potential to restore GBM integrity in patients harboring nonsense variants.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0330804","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:33:45Z","timestamp":1766169225000},"page":"e0330804","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anticodon-edited tRNA enables translational readthrough of COL4A5 premature termination codons"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0160-3271","authenticated-orcid":true,"given":"Kohei","family":"Omachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Lueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1510-8714","authenticated-orcid":true,"given":"Jeffrey H.","family":"Miner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"6","key":"pone.0330804.ref001","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1172\/JCI115510","article-title":"Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis","volume":"88","author":"A Hamosh","year":"1991","journal-title":"J Clin Invest"},{"issue":"1","key":"pone.0330804.ref002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"D Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"pone.0330804.ref003","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1172\/JCI92707","article-title":"Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients","volume":"127","author":"DT Woodley","year":"2017","journal-title":"J Clin Invest"},{"issue":"28","key":"pone.0330804.ref004","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1803154115","article-title":"Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa","volume":"115","author":"V Lincoln","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"pone.0330804.ref005","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ymthe.2020.03.006","article-title":"Gentamicin induces laminin 332 and improves wound healing in junctional epidermolysis bullosa patients with nonsense mutations","volume":"28","author":"A Kwong","year":"2020","journal-title":"Mol Ther"},{"issue":"2","key":"pone.0330804.ref006","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/jpet.120.265595","article-title":"ELX-02 generates protein via premature stop codon read-through without inducing native stop codon read-through proteins","volume":"374","author":"DK Crawford","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"pone.0330804.ref007","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","article-title":"Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids","volume":"20","author":"DK Crawford","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"14","key":"pone.0330804.ref008","doi-asserted-by":"crossref","first-page":"6583","DOI":"10.1093\/nar\/gkw638","article-title":"Novel small molecules potentiate premature termination codon readthrough by aminoglycosides","volume":"44","author":"A Baradaran-Heravi","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"pone.0330804.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216423","article-title":"The antimalarial drug mefloquine enhances TP53 premature termination codon readthrough by aminoglycoside G418","volume":"14","author":"MW Ferguson","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"pone.0330804.ref010","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41467-019-08329-4","article-title":"Engineered transfer RNAs for suppression of premature termination codons","volume":"10","author":"JD Lueck","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"pone.0330804.ref011","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1641","article-title":"Therapeutic promise of engineered nonsense suppressor tRNAs","volume":"12","author":"JJ Porter","year":"2021","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"3","key":"pone.0330804.ref012","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41587-022-01252-y","article-title":"tRNA therapeutics burst onto startup scene","volume":"40","author":"E Dolgin","year":"2022","journal-title":"Nat Biotechnol"},{"key":"pone.0330804.ref013","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.omtn.2022.04.033","article-title":"Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs","volume":"28","author":"W Ko","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"pone.0330804.ref014","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s10020-018-0024-7","article-title":"Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons","volume":"24","author":"M Dabrowski","year":"2018","journal-title":"Mol Med"},{"issue":"6","key":"pone.0330804.ref015","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.chembiol.2010.06.003","article-title":"Probing translation with small-molecule inhibitors","volume":"17","author":"SC Blanchard","year":"2010","journal-title":"Chem Biol"},{"key":"pone.0330804.ref016","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52611","article-title":"Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides","volume":"9","author":"JR Wangen","year":"2020","journal-title":"Elife"},{"issue":"3454","key":"pone.0330804.ref017","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/bmj.1.3454.504","article-title":"Hereditary familial congenital haemorrhagic nephritis","volume":"1","author":"AC Alport","year":"1927","journal-title":"Br Med J"},{"issue":"25","key":"pone.0330804.ref018","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1056\/NEJMra022296","article-title":"Alport\u2019s syndrome, Goodpasture\u2019s syndrome, and type IV collagen","volume":"348","author":"BG Hudson","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0330804.ref019","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0021-9258(18)52397-8","article-title":"Use of the polymerase chain reaction to clone and sequence a cDNA encoding the bovine alpha 3 chain of type IV collagen","volume":"266","author":"KE Morrison","year":"1991","journal-title":"J Biol Chem"},{"issue":"3","key":"pone.0330804.ref020","first-page":"545","article-title":"Sequence and localization of a partial cDNA encoding the human alpha 3 chain of type IV collagen","volume":"49","author":"KE Morrison","year":"1991","journal-title":"Am J Hum Genet"},{"issue":"1","key":"pone.0330804.ref021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/ng0994-77","article-title":"Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome","volume":"8","author":"T Mochizuki","year":"1994","journal-title":"Nat Genet"},{"issue":"4960","key":"pone.0330804.ref022","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.2349482","article-title":"Identification of mutations in the COL4A5 collagen gene in Alport syndrome","volume":"248","author":"DF Barker","year":"1990","journal-title":"Science"},{"issue":"22","key":"pone.0330804.ref023","doi-asserted-by":"crossref","first-page":"14112","DOI":"10.1093\/nar\/gkae1112","article-title":"Optimization of ACE-tRNAs function in translation for suppression of nonsense mutations","volume":"52","author":"JJ Porter","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"pone.0330804.ref024","doi-asserted-by":"crossref","first-page":"31791","DOI":"10.1038\/s41598-024-82766-0","article-title":"Engineered tRNAs efficiently suppress CDKL5 premature termination codons","volume":"14","author":"S Pezzini","year":"2024","journal-title":"Sci Rep"},{"key":"pone.0330804.ref025","doi-asserted-by":"crossref","first-page":"102032","DOI":"10.1016\/j.omtn.2023.102032","article-title":"Transfer RNA-mediated restoration of potassium current and electrical correction in premature termination long-QT syndrome hERG mutants","volume":"34","author":"VG Blomquist","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"issue":"22","key":"pone.0330804.ref026","doi-asserted-by":"crossref","first-page":"14244","DOI":"10.1093\/nar\/gkae1048","article-title":"Efficient suppression of premature termination codons with alanine by engineered chimeric pyrrolysine tRNAs","volume":"52","author":"A Awawdeh","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"pone.0330804.ref027","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf532","article-title":"An engineered glutamic acid tRNA for efficient suppression of pathogenic nonsense mutations","volume":"53","author":"C Specht","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"pone.0330804.ref028","article-title":"ACE-tRNAs are a platform technology for suppressing nonsense mutations that cause cystic fibrosis","volume":"53","author":"W Ko","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"7905","key":"pone.0330804.ref029","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41586-022-04533-3","article-title":"AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice","volume":"604","author":"J Wang","year":"2022","journal-title":"Nature"},{"issue":"7966","key":"pone.0330804.ref030","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41586-023-06133-1","article-title":"Engineered tRNAs suppress nonsense mutations in cells and in vivo","volume":"618","author":"S Albers","year":"2023","journal-title":"Nature"},{"issue":"18","key":"pone.0330804.ref031","article-title":"Small-molecule eRF3a degraders rescue CFTR nonsense mutations by promoting premature termination codon readthrough","volume":"132","author":"RE Lee","year":"2022","journal-title":"J Clin Invest"},{"issue":"3","key":"pone.0330804.ref032","doi-asserted-by":"crossref","first-page":"103891","DOI":"10.1016\/j.isci.2022.103891","article-title":"NanoLuc reporters identify COL4A5 nonsense mutations susceptible to drug-induced stop codon readthrough","volume":"25","author":"K Omachi","year":"2022","journal-title":"iScience"},{"issue":"5","key":"pone.0330804.ref033","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2018.02.003","article-title":"A split-luciferase-based trimer formation assay as a high-throughput screening platform for therapeutics in alport syndrome","volume":"25","author":"K Omachi","year":"2018","journal-title":"Cell Chem Biol"},{"key":"pone.0330804.ref034","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.33178","article-title":"ICE1 promotes the link between splicing and nonsense-mediated mRNA decay","volume":"7","author":"TD Baird","year":"2018","journal-title":"Elife"},{"issue":"7","key":"pone.0330804.ref035","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41580-019-0126-2","article-title":"Quality and quantity control of gene expression by nonsense-mediated mRNA decay","volume":"20","author":"T Kurosaki","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"pone.0330804.ref036","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.15252\/emmm.201404461","article-title":"5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion","volume":"6","author":"M Bhuvanagiri","year":"2014","journal-title":"EMBO Mol Med"},{"issue":"10","key":"pone.0330804.ref037","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1073\/pnas.1424127112","article-title":"Nonsense suppression by near-cognate tRNAs employs alternative base pairing at codon positions 1 and 3","volume":"112","author":"B Roy","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"pone.0330804.ref038","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1681\/ASN.2009070784","article-title":"Genotype-phenotype correlation in X-linked Alport syndrome","volume":"21","author":"MR Bekheirnia","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"pone.0330804.ref039","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.kint.2020.06.038","article-title":"Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome","volume":"98","author":"T Yamamura","year":"2020","journal-title":"Kidney Int"},{"issue":"34","key":"pone.0330804.ref040","first-page":"31142","article-title":"Crystal structure of NC1 domains. Structural basis for type IV collagen assembly in basement membranes","volume":"277","author":"M Sundaramoorthy","year":"2002","journal-title":"J Biol Chem"},{"issue":"17","key":"pone.0330804.ref041","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1093\/nar\/13.17.6265","article-title":"Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin","volume":"13","author":"JF Burke","year":"1985","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"pone.0330804.ref042","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molmed.2023.01.004","article-title":"Readthrough compounds for nonsense mutations: bridging the translational gap","volume":"29","author":"S Spelier","year":"2023","journal-title":"Trends Mol Med"},{"key":"pone.0330804.ref043","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev-genom-091212-153527","article-title":"Therapeutics based on stop codon readthrough","volume":"15","author":"KM Keeling","year":"2014","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"1","key":"pone.0330804.ref044","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1038\/s41598-022-06525-9","article-title":"Genotype-phenotype correlations for COL4A3-COL4A5 variants resulting in Gly substitutions in Alport syndrome","volume":"12","author":"JT Gibson","year":"2022","journal-title":"Sci Rep"},{"issue":"13","key":"pone.0330804.ref045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.158397","article-title":"Amelioration of muscle and nerve pathology of Lama2-related dystrophy by AAV9-laminin-\u03b1LN linker protein","volume":"7","author":"KK McKee","year":"2022","journal-title":"JCI Insight"},{"issue":"677","key":"pone.0330804.ref046","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo1815","article-title":"Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy","volume":"15","author":"SM Birch","year":"2023","journal-title":"Sci Transl Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:33:53Z","timestamp":1766169233000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330804"}},"subtitle":[],"editor":[{"given":"Georg","family":"Stoecklin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330804","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}